Millendo therapeutics, inc. (OVAS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-46,200

-44,568

-41,727

-37,986

-33,157

-27,177

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

126

97

61

36

34

32

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

4,458

4,317

3,798

3,025

2,189

1,427

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use asset

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency loss

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-65,090

-75,015

-75,397

-82,260

-80,218

-78,849

-77,771

-73,219

-71,508

-66,509

-58,912

-49,520

-41,630

-35,598

-31,701

-29,044

0

0

0

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

1,904

2,122

2,195

2,238

2,183

1,953

1,590

1,286

936

702

584

450

324

279

250

231

0

0

0

Amortization of (discount) premium on debt securities

-

-

-

-

-

-

-

-

-

-

153

252

391

659

931

1,174

1,240

1,116

1,025

926

893

871

815

745

627

586

0

0

0

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

7,367

9,416

7,024

9,215

13,145

14,336

16,521

19,337

20,789

20,043

17,907

12,407

7,299

5,965

5,124

5,094

0

0

0

Issuance of common stock for director fees

-

-

-

-

-

-

-

-

-

-

140

151

154

154

281

242

203

165

0

0

0

-

-

-

-

-

-

-

-

Net loss on equity method investment

-

-

-

-

-

-

-

-

-

-

-1,386

-1,610

-1,572

-1,542

-1,556

-1,508

-1,481

-1,561

0

0

0

-

-

-

-

-

-

-

-

Net loss on equity method investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,271

698

2,074

4,673

2,520

2,524

480

-270

-378

-1,002

-1,038

-373

-934

-946

-1,324

-1,218

404

1,113

2,093

2,187

1,281

997

612

335

128

76

0

0

0

Other assets

-124

-66

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

462

-469

1,065

1,743

920

320

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-22

844

-1,372

-1,178

-671

-1,480

864

-171

285

1,471

259

2,317

1,256

1,172

607

-721

0

0

0

Accrued expenses and other liabilities

-683

281

168

1,902

2,372

3,240

5,914

2,477

1,422

-1,394

-1,815

176

849

4,809

3,385

4,738

5,001

752

-769

-2,011

-1,455

2,301

4,381

4,113

3,261

2,972

0

0

0

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash used in operating activities

-40,782

-41,222

-38,757

-35,123

-29,251

-23,647

2,818

-2,763

-10,152

-20,340

-52,548

-57,680

-61,509

-61,734

-58,084

-55,170

-51,302

-50,286

0

0

0

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Investment in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,500

-

1,500

1,500

750

1,500

0

0

0

-

-

-

-

Purchase of property and equipment

413

397

380

306

45

36

-88

-90

-70

4

1,653

1,819

2,291

2,586

3,951

4,949

5,210

5,229

0

0

0

-

-

-

-

719

0

0

0

Proceeds from sale of marketable securities

1,399

4,385

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash paid in Alizé asset purchase

-

-

-

-

-

524

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

94,844

86,832

74,524

72,013

57,432

55,212

55,312

53,528

45,081

40,206

35,113

20,797

0

0

0

-

-

-

-

Proceeds from sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,431

0

0

0

-

-

-

-

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

65,441

99,005

82,115

82,671

78,786

53,449

122,343

95,225

82,072

68,917

41,330

57,603

0

0

0

-

-

-

-

(Decrease) increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

593

-

0

0

0

-

-

-

-

-

-

-

-

Cash (used in) provided by investing activities

986

3,988

6,497

6,571

5,433

1,932

-18,860

-6,728

3,245

458

27,200

-14,992

12,316

8,292

3,689

26,808

-63,517

-38,290

0

0

0

-

-

-

-

-

-

-

-

Financing activities:
Repayment of debt

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing costs

182

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Proceeds from the issuance of common stock, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

124,242

124,157

124,135

51,733

51,480

51,399

51,423

32,414

0

0

0

Proceeds from option and warrant exercises

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of principal on finance lease

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuances of common stock under benefit plans, net of withholding taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Cash provided by (used in) financing activities

32,592

26,943

70,693

78,272

77,727

77,744

2,671

-5,029

-4,506

-4,463

-7

88

54,148

54,148

54,033

54,018

599

125,386

0

0

0

-

-

-

-

-

-

-

-

Effect of foreign currency exchange rate changes on cash

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-7,194

-10,258

38,580

49,807

53,983

56,147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-25,355

-72,584

4,955

706

-362

25,656

-114,220

36,810

38,717

53,685

78,564

-11,664

-8,952

-11,640

12,946

3,302

0

0

0

Alizé acquisition costs included in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs in accounts payable and accrued expenses

0

-

-

-61

28

15

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-